Article
Oncology
Dapeng Li, Yihebali Chi, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng, Zhengang Xu, Xiangqian Zheng, Pingzhang Tang, Ming Gao
Summary: Anlotinib demonstrated significant improvement in progression-free survival and objective response rate in patients with MTC, with a higher incidence of treatment-related adverse events. However, it showed relatively reliable safety profile in this population.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Marcia S. Brose, Bruce Robinson, Steven Sherman, Jolanta Krajewska, Chia-Chi Lin, Fernanda Vaisman, Ana Hoff, Erika Hitre, Daniel W. Bowles, Jorge Hernando, Leonardo Faoro, Kamalika Banerjee, Jennifer W. Oliver, Bhumsuk Keam, Jaume Capdevila
Summary: Patients with radioiodine-refractory differentiated thyroid cancer who have previously undergone VEGFR-targeted therapy and have no available standard of care were evaluated in this study for the tyrosine kinase inhibitor cabozantinib. Results showed that cabozantinib significantly prolonged progression-free survival, potentially offering a new treatment option for these patients.
Article
Oncology
Bradley J. Monk, Takafumi Toita, Xiaohua Wu, Juan C. Vazquez Limon, Rafal Tarnawski, Masaki Mandai, Ronnie Shapira-Frommer, Umesh Mahantshetty, Maria del Pilar Estevez-Diz, Qi Zhou, Sewanti Limaye, Francisco J. Ramirez Godinez, Christina Oppermann Kussler, Szilvia Varga, Natalia Valdiviezo, Daisuke Aoki, Manuel Leiva, Jung-Yun Lee, Raymond Sulay, Yulia Kreynina, Wen-Fang Cheng, Felipe Rey, Yi Rong, Guihao Ke, Sophie Wildsmith, Andrew Lloyd, Hannah Dry, Ana Tablante Nunes, Jyoti Mayadev
Summary: This study assessed the benefit of adding durvalumab, a PD-L1 antibody, with and following chemoradiotherapy for locally advanced cervical cancer. The results showed that the addition of durvalumab did not significantly improve progression-free survival, but it may have potential efficacy in patients with high tumoral PD-L1 expression.
Article
Oncology
Yansong Lin, Shukui Qin, Zhiyong Li, Hui Yang, Wei Fu, Shaohua Li, Wenxin Chen, Zairong Gao, Weibing Miao, Huiqin Xu, Qing Zhang, Xinming Zhao, Jiandong Bao, Linfa Li, Yuan Ren, Chenghe Lin, Shanghua Jing, Qingjie Ma, Jun Liang, Guang Chen, Hong Zhang, Yifan Zhang, Xianfeng Zhou, Yaxiong Sang, Zhiguo Hou
Summary: The study aimed to assess the efficacy and safety of apatinib in patients with progressive locally advanced or metastatic RAIR-DTC. Results showed that apatinib demonstrated significant clinical benefits in terms of prolonged PFS and improved overall survival with manageable safety profile.
Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Article
Endocrinology & Metabolism
Yan-Song Lin, Hui Yang, Yong Ding, Yi-Zhuang Cheng, Feng Shi, Jian Tan, Zhi-Yong Deng, Zhen-Dong Chen, Rong-Fu Wang, Qing-Hai Ji, Rui Huang, Lin-Fa Li
Summary: The study evaluated the efficacy and safety of the new multikinase inhibitor donafenib in treating locally advanced or metastatic RAIR-DTC. Both 200mg and 300mg doses of donafenib showed similar efficacy in terms of objective response rate, with the 300mg dose demonstrating a trend towards longer progression-free survival and more tumor shrinkage. The most common grade 3 treatment-related adverse events were palmar-plantar erythrodysesthesia and hypertension.
Article
Oncology
Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M. Schuetze, Bruno Vincenzi, Andrew J. Wagner, Bartosz Chmielowski, Robin L. Jones, Richard F. Riedel, Silvia Stacchiotti, Elizabeth T. Loggers, Kristen N. Ganjoo, Axel Le Cesne, Antoine Italiano, Xavier Garcia Del Muro, Melissa Burgess, Sophie Piperno-Neumann, Christopher Ryan, Mary F. Mulcahy, Charles Forscher, Nicolas Penel, Scott Okuno, Anthony Elias, Lee Hartner, Tony Philip, Thierry Alcindor, Bernd Kasper, Peter Reichardt, Lore Lapeire, Jean-Yves Blay, Christine Chevreau, Claudia Maria Valverde Morales, Gary K. Schwartz, James L. Chen, Hari Deshpande, Elizabeth J. Davis, Garth Nicholas, Stefan Groeschel, Helen Hatcher, Florence Duffaud, Antonio Casado Herraez, Roberto Diaz Beveridge, Giuseppe Badalamenti, Mikael Eriksson, Christian Meyer, Margaret von Mehren, Brian A. Van Tine, Katharina Gotze, Filomena Mazzeo, Alexander Yakobson, Aviad Zick, Alexander Lee, Anna Estival Gonzalez, Andrea Napolitano, Mark A. Dickson, Dayana Michel, Changting Meng, Lingling Li, Jianjun Liu, Osnat Ben-Shahar, Dane R. Van Domelen, Christopher J. Walker, Hua Chang, Yosef Landesman, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Steven Attia
Summary: The clinical benefit of Selinexor in patients with advanced DD-LPS has been evaluated. The results showed that Selinexor improved PFS and time to next treatment compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Yansong Lin, Shukui Qin, Hui Yang, Feng Shi, Aimin Yang, Xingmin Han, Bin Liu, Zhiyong Li, Qinghai Ji, Lijun Tang, Zhiyong Deng, Yong Ding, Wei Fu, Xianhe Xie, Linfa Li, Xiaohui He, Zhongwei Lv, Qingjie Ma, Zan Shen, Zhuming Guo, Zhendong Chen, Yali Cui, Jian Tan, Zairong Gao, Shanghua Jing, Keyi Lu, Xianyang Luo, Yuan Zhang, Yong Fang, Zhendong Li, Yizhuang Cheng, Shangtong Lei, Sha Luan, Guang Chen, Guihua Wang, Liqing Wu, Lingling Liu
Summary: The purpose of this study was to evaluate the antitumor activity and safety of donafenib in Chinese patients with RAIR-DTC. The results showed that donafenib significantly improved PFS, ORR, and DCR compared to placebo, with common adverse events including hypertension and hand-foot syndrome. The study suggests that donafenib could be a new treatment option for patients with RAIR-DTC.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
D. Miles, J. Gligorov, F. Andre, D. Cameron, A. Schneeweiss, C. Barrios, B. Xu, A. Wardley, D. Kaen, L. Andrade, V Semiglazov, M. Reinisch, S. Patel, M. Patre, L. Morales, S. L. Patel, M. Kaul, T. Barata, J. O'Shaughnessy
Summary: Combining atezolizumab with paclitaxel did not improve PFS or OS in PD-L1-positive aTNBC patients, although it showed some advantage in unconfirmed best overall response rate and duration of response.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Juan W. Valle, Arndt Vogel, Crystal S. Denlinger, Aiwu Ruth He, Li-Yuan Bai, Rashida Orlova, Eric Van Cutsem, Jorge Adeva, Li-Tzong Chen, Radka Obermannova, Thomas J. Ettrich, Jen-Shi Chen, Harpreet Wasan, Allicia C. Girvan, Wei Zhang, Jiangang Liu, Chunlao Tang, Philip J. Ebert, Amit Aggarwal, Samuel C. McNeely, Brian A. Moser, Joana M. Oliveira, Roberto Carlesi, Richard A. Walgren, Do-Youn Oh
Summary: This study investigated the efficacy and safety of adding ramucirumab or merestinib to first-line cisplatin-gemcitabine in patients with biliary tract cancer. The results showed that these treatment regimens were well tolerated but did not improve progression-free survival in patients with this type of cancer.
Article
Oncology
Syed A. Hussain, Jason F. Lester, Richard Jackson, Matthew Gornall, Muneeb Qureshi, Anthony Elliott, Simon J. Crabb, Robert A. Huddart, Naveen Vasudev, Alison J. Birtle, Jane Worlding, Nicholas D. James, Omi Parikh, Maria Vilarino-Varela, Roberto Alonzi, Mark D. Linch, Irbaz B. Riaz, James W. F. Catto, Thomas Powles, Robert J. Jones
Summary: This study investigated the effect of adding nintedanib to neoadjuvant chemotherapy in muscle-invasive bladder cancer, and found that nintedanib did not improve the rate of pathological complete response.
Article
Medicine, General & Internal
Christopher Sweeney, Sergio Bracarda, Cora N. Sternberg, Kim N. Chi, David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Boris Alekseev, Francis Parnis, Vagif Atduev, Gary L. Buchschacher, Rustem Gafanov, Luis Corrales, Michael Borre, Daniil Stroyakovskiy, Gustavo Vasconcelos Alves, Evangelos Bournakis, Javier Puente, Marie-Laurence Harle-Yge, Jorge Gallo, Geng Chen, Justin Hanover, Matthew J. Wongchenko, Josep Garcia, Johann S. de Bono
Summary: The combination of ipatasertib and abiraterone significantly improved radiographical progression-free survival in patients with mCRPC with PTEN-loss tumors, but there was no significant difference between the groups in the intention-to-treat population. Adverse events were consistent with the known safety profiles of each agent, suggesting a potential treatment for men with PTEN-loss mCRPC.
Article
Oncology
Florence Duffaud, Antoine Italiano, Emannuelle Bompas, Maria Rios, Nicolas Penel, Olivier Mir, Sophie Piperno-Neumann, Christine Chevreau, Corinne Delcambre, Francois Bertucci, Pascaline Boudou-Rouquette, Mathilde Cancel, Christophe Perrin, Esma Saada-Bouzid, Laure Monard, Camille Schiffler, Loic Chaigneau, Alice Hervieu, Olivier Collard, Corinne Bouvier, Vincent Vidal, Sylvie Chabaud, Jean-Yves Blay
Summary: This multi-cohort trial investigated the efficacy and safety of regorafenib for advanced sarcomas of bone origin, focusing on patients with metastatic or locally advanced chondrosarcoma progressing after prior chemotherapy. While the primary endpoint was not statistically met in this small randomized cohort, there is modest evidence suggesting that regorafenib may slow disease progression in patients with metastatic CS after prior chemotherapy failure.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Zhihao Lu, Junye Wang, Yongqian Shu, Lianke Liu, Li Kong, Lei Yang, Buhai Wang, Guogui Sun, Yinghua Ji, Guochun Cao, Hu Liu, Tongjian Cui, Na Li, Wensheng Qiu, Gaofeng Li, Xinfang Hou, Hui Luo, Liying Xue, Yanqiao Zhang, Wenbin Yue, Zheng Liu, Xiuwen Wang, Shegan Gao, Yueyin Pan, Marie-Pierre Galais, Aziz Zaanan, Zhuo Ma, Haoyu Li, Yan Wang, Lin Shen
Summary: This study evaluated the efficacy of sintilimab in combination with chemotherapy for patients with unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. The results demonstrated significant improvements in overall survival and progression free survival with sintilimab plus cisplatin and paclitaxel compared to placebo plus chemotherapy. Similar benefits were seen with sintilimab plus cisplatin and 5-fluorouracil.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Raymond Hang Wun Li, Sue Seen Tsing Lo, Kristina Gemzell-Danielsson, Carol Ho Yi Fong, Pak Chung Ho, Ernest Hung Yu Ng
Summary: This study found that co-administration of oral piroxicam 40 mg with levonorgestrel improved the efficacy of emergency contraception. The use of piroxicam could be considered in clinical settings where levonorgestrel emergency contraception is the chosen option.
Editorial Material
Oncology
S. Filetti, C. Durante, D. M. Hartl, S. Leboulleux, L. D. Locati, K. Newbold, M. G. Papotti, A. Berruti
ANNALS OF ONCOLOGY
(2022)
Article
Oncology
Eva Ellebaek, Aimilia Schina, Henrik Schmidt, Charlotte Aaquist Haslund, Lars Bastholt, Inge Marie Svane, Marco Donia
Summary: This study found that initiation of immunotherapy in summer is associated with prolonged survival in patients with BRAF wild-type melanoma in Denmark.
PIGMENT CELL & MELANOMA RESEARCH
(2023)
Editorial Material
Oncology
Neel Maria Helvind, Marie Brinch-Moller Weitemeyer, Annette Hougaard Chakera, Helle Westergren Hendel, Eva Ellebaek, Inge Marie Svane, Mette Wanscher Kjaerskov, Sophie Bojesen, Helle Skyum, Soren Kjaer Petersen, Lars Bastholt, Christoffer Johansen, Pernille Envold Bidstrup, Lisbet Rosenkrantz Holmich
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
M. Bensiali, N. Anizan, S. Leboulleux, S. Lamart, E. Davesne, D. Broggio, A. Desbree, D. France
Summary: The OEDIPE software was developed with new functionalities to handle multiple 3D or planar images and a SPECT image for patient-specific dosimetry. Methods were implemented to recover patient biokinetics and validate the software using phantom images and whole-body retention data. Results showed good agreement between the estimated activities and cumulated activities from the software and reference values.
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
(2023)
Article
Oncology
Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de la Fouchardiere, Brett G. M. Hughes, Andrew G. Gianoukakis, Young Joo Park, Ilia Romanov, Monika K. Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A. Binder, Nicholas Sauter, Ran Xie, Marcia S. Brose
Summary: In this study comparing the starting dose of lenvatinib 18 mg/day with 24 mg/day in RR-DTC patients, no significant difference was found in the health-related quality of life (HRQoL). These findings support the use of the approved lenvatinib starting dose of 24 mg/day in RR-DTC patients.
Article
Oncology
Neel Maria Helvind, Marie Brinch-Moller Weitemeyer, Annette Hougaard Chakera, Helle Westergren Hendel, Eva Ellebaek, Inge Marie Svane, Mette Wanscher Kjaerskov, Sophie Bojesen, Helle Skyum, Soren Kjaer Petersen, Lars Bastholt, Christoffer Johansen, Pernille Envold Bidstrup, Lisbet Rosenkrantz Holmich
Summary: This study aimed to determine the impact of surveillance with routine FDG PET-CT on hazard, cumulative incidence, and absolute risk of overall, locoregional, and distant recurrence detection in patients with stage IIB to IIID cutaneous melanoma. The study found that patients with stage IIB to IIID melanoma followed with routine FDG PET-CT had a 51% increased hazard of distant recurrence detection within the first two years of surveillance.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, David Taieb, Stephane Bardet, Marie Terroir-Cassou-Mounat, Nadege Anizan, Emilie Bouvier-Morel, Livia Lamartina, Georges Lion, Sarah Betrian, Christophe Sajous, Aurelie Schiazza, Marie-Eve Garcia, Renaud Ciappuccini, Martin Schlumberger, Abir Al Ghuzlan, Yan Godbert, Isabelle Borget
Summary: Dabrafenib-trametinib is effective for restoring iodine uptake in BRAF p.V600E-mutated DTC patients, with a 6-month partial response observed in 38% of patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Endocrinology & Metabolism
Sophie Leboulleux, Daniele Benisvy, David Taieb, Marie Attard, Claire Bournaud, Marie Terroir-Cassou-Mounat, Ludovic Lacroix, Nadege Anizan, Aurelie Schiazza, Marie Eve Garcia, Abir Al Ghuzlan, Livia Lamartina, Martin Schlumberger, Yann Godbert, Isabelle Borget
Review
Endocrinology & Metabolism
Paulina Kuczma, Marco Stefano Demarchi, Sophie Leboulleux, Christophe Tresallet, Maria Mavromati, Reza Djafarrian, Andrea Mabilia, Frederic Triponez
Summary: The most common site of lymph node metastases in papillary thyroid carcinoma is the central compartment of the neck (level VI). Prophylactic surgical clearance of the level VI in the absence of clinically suspicious lymph nodes (cN0) is still under debate. Arguments against the prophylactic central lymph node dissection (CLND) cite minimal oncologic benefit and concomitant higher operative morbidity. Recently, near-infrared fluorescence imaging has emerged as a potential tool to minimize the risk of hypoparathyroidism associated with CLND.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Oncology
Rossella Elisei, Enrique Grande, Michael C. Kreissl, Sophie Leboulleux, Tarun Puri, Nicolas Fasnacht, Jaume Capdevila
Summary: The incidence of thyroid cancer is increasing globally, with Europe ranking second in disease burden after Asia. Over the past few decades, research has identified key molecular pathways and targetable kinases/drivers for each histologic subtype of thyroid cancer. Newer and selective RET inhibitors, such as selpercatinib and pralsetinib, have shown promising efficacy and favorable toxicity profiles in clinical trials for the treatment of RET-driven advanced thyroid cancer. Genetic testing is crucial to identify RET alterations and determine the optimal treatment approach.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Anne Vest Soerensen, Jakob Kjellberg, Rikke Ibsen, Lars Bastholt, Henrik Schmidt, Inge Marie Svane
Summary: This study aimed to investigate the health care costs and loss of productivity after implementing new agents for metastatic melanoma. The results showed that the implementation of targeted therapy and checkpoint inhibitors increased medicine costs more than three-fold for long-term survivors. However, total health care costs excluding medicine costs were lower for long-term survivors in 2012-2016 compared to 2007-2011. Importantly, productivity increased for long-term survivors in 2012-2016.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Ketty Peris, Maria Concetta Fargnoli, Roland Kaufmann, Petr Arenberger, Lars Bastholt, Nicole Basset Seguin, Veronique Bataille, Lieve Brochez, Veronique del Marmol, Reinhard Dummer, Ana-Marie Forsea, Caroline Gaudy-Marqueste, Catherine A. Harwood, Axel Hauschild, Christoph Hoeller, Lidija Kandolf, Nicole W. J. Kellerners-Smeets, Aimilios Lallas, Ulrike Leiter, Josep Malvehy, Branka Marinovic, Zeljko Mijuskovic, David Moreno-Ramirez, Eduardo Nagore, Paul Nathan, Alexander J. Stratigos, Eggert Stockfleth, Luca Tagliaferri, Myrto Trakatelli, Ricardo Vieira, Iris Zalaudek, Claus Garbe, EADO, EDF, ESTRO, UEMS, V EAD
Summary: Basal cell carcinoma is the most common malignant tumor in white populations. This article provides updated recommendations on the diagnosis and treatment of BCC, including classification, surgical treatment, topical therapies, and the use of hedgehog inhibitors and immunotherapy. Regular skin examinations and long-term follow-up are also recommended for high-risk patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Dermatology
Neel M. Helvind, Marie Brinch-Moller Weitemeyer, Annette H. Chakera, Helle W. Hendel, Eva Ellebaek, Inge Marie Svane, Mette W. Kjaerskov, Sophie Bojesen, Helle Skyum, Soren K. Petersen, Lars Bastholt, Christoffer Johansen, Pernille E. Bidstrup, Lisbet R. Holmich
Summary: This study found that the current clinical staging system does not accurately reflect the risk of recurrence and mortality in melanoma. A high proportion of distant recurrences suggests that hematogenous spread is more common than previously assumed. Routine functional/cross-sectional imaging should be considered for surveillance of patients with stage IIB to IV melanoma. Future research should focus on developing new risk stratification tools and determining the impact of routine imaging on prognosis.
Article
Endocrinology & Metabolism
Maria Mavromati, Thomas Mavrakanas, Francois R. Jornayvaz, Karl Schaller, Aikaterini Fitsiori, Maria I. Vargas, Johannes A. Lobrinus, Doron Merkler, Kristof Egervari, Jacques Philippe, Sophie Leboulleux, Shahan Momjian
Summary: This study assessed the impact of transsphenoidal surgery on pituitary function in patients with non-functioning pituitary adenomas (NFPAs) and identified predictive factors. The results showed that the recovery rate of pituitary deficiency after surgery was 46% and the rate of new pituitary deficiency was 10%. Male patients and patients with hyperprolactinemia were more likely to experience pituitary function recovery. Rating: 8/10
Article
Oncology
Aimilia Schina, Sidsel Pedersen, Anne -Louise Spenning, Olivia Kaas Laursen, Cecilia Pedersen, Charlotte Aaquist Haslund, Henrik Schmidt, Lars Bastholt, Inge Marie Svane, Eva Ellebaek, Marco Donia
Summary: This study analyzed the real-world impact of modern treatments on the long-term survival of patients with metastatic melanoma. The introduction of therapies such as anti-PD-1 led to sustained improved survival in patients, regardless of their eligibility for clinical trials. A prognostic model was developed to predict the survival of newly diagnosed patients, providing a useful tool for improving patient information.
EUROPEAN JOURNAL OF CANCER
(2023)